40425_2019_828_MOESM1_ESM.docx (294.13 kB)
MOESM1 of Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
journal contribution
posted on 2019-12-06, 04:45 authored by Nikolaus Wagner, Benjamin Weide, Mirko Gries, Maike Reith, Kathrin Tarnanidis, Valerie Schuermans, Charlotte Kemper, Coretta Kehrel, Anne Funder, Ramtin Lichtenberger, Antje Sucker, Esther Herpel, Tim Holland-Letz, Dirk Schadendorf, Claus Garbe, Viktor Umansky, Jochen Utikal, Christoffer GebhardtAdditional file 1: Figure S1. PIQOR microarray assay reveals strong expression of S100A8 and S100A9 in melanoma metastases. Figure S2. S100A8/A9 predicts overall survival in stage III and in stage IV melanoma patients. Figure S3. Combinatory analysis of S100B and LDH with S100A8/A9 in serum of stage III and stage IV patients of the combined training and independent validation sets. Figure S4. Survival analysis of serum S100A8/A9 in stage III patient with normal levels of LDH or S100B. Table S1. Main characteristics of the tissue microarray sets. Table S2. Main characteristics of the serum marker sets. Table S3. Multivariate analysis of serum marker proteins and overall survival in stage III patients of the combined training and independent validation sets. Table S4. Multivariate analysis of serum marker proteins and overall survival in stage IV patients of the combined training and independent validation sets. Table S5. Main characteristics of the pembrolizumab sets.
